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Correspondence to: Marı́a José Soler; E-mail: mjsoler01@gmail.com; Daniel Batlle; E-mail: d-batlle@northwestern.edu
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2), the coronavirus that causes the infection known as coronavirus
disease 2019 (COVID-19), has spread rapidly causing a pandemic
that has not only seriously affected human health, but also re-
stricted daily life activities and weakened the world economy to
unprecedented levels. Most people who are COVID-19-positive for-
tunately present with mild symptoms, but older people and those
with comorbidities may present with severe respiratory complica-
tions, often requiring care in intensive medical units. As of the
end of January 2021, mortality worldwide attributable to COVID-19
has been estimated at 2 150 000. The death rate per 100 000 popu-
lation as reported by the John Hopkins Coronavirus Resource
Centre is depicted in Figure 1. The impact of COVID-19 on the ne-
phrology community has been important at different levels: (i)
patients with end-stage kidney disease on dialysis and those with
kidney transplants are at risk for COVID-19 complications and the
mortality is high; (ii) acute kidney injury (AKI) ascribed to COVID-
19 is a frequent complication of severe cases and moreover is as-
sociated with high mortality; and (iii) there is COVID-19-related
glomerular involvement, characterized in some cases by collaps-
ing glomerulopathy and tubular damage in other cases.
All of this COVID-19-related kidney pathology adds greatly
to the already high global burden of kidney disease in terms of
human suffering and costs to the medical systems. It is esti-
mated that the number of people that suffer from kidney dis-
ease in the world exceeds 850 million, which is twice the
estimated number of people with diabetes (422 million). This
places kidney disease among one of the most common of all
diseases around the world [1]. In-hospital patients seen by
nephrologists, moreover, are the more complex, with the high-
est morbidity and mortality [2]. We do not know yet the long-
term outcomes of COVID-19-related kidney disease in terms of
recovery of kidney function or persistence of proteinuria, which
could add additional need for nephrology care. Taking all of this
into consideration, the impact of COVID-19 in the nephrology
community and our patients could be potentially devastating.
An analysis of over 17 million adults found almost 11 000
COVID-19-related deaths [3]. Advanced chronic kidney disease
(CKD) was identified as one of the most important risk factors
for death in COVID-19 patients in this order: dialysis patients
[adjusted Hazard Ratio (aHR) 3.69], transplant recipients (aHR
3.53) and CKD (estimated glomerular filtration rate <30 mL/min/
1.73 m2) (aHR 2.52) [4]. The COVID-19 mortality risk in CKD
patients is actually greater than the risk observed in people
with diabetes and chronic heart disease, suggesting priority for
clinical trials, vaccinations and future action plans in our ne-
phrology field [4]. Results from the European Renal Association
COVID-19 Database (ERACODA) revealed a 28-day mortality in
kidney transplant and dialysis patients with COVID-19 as high
as 21.3 and 25%, respectively [5]. Hypertension, diabetes melli-
tus, coronary artery disease, heart failure and chronic lung dis-
ease were not identified as independent risk factors [6]. In
concordance with these results, a study from Dialysis Clinic
Inc., a national not-for-profit dialysis provider caring for >15 000
maintenance dialysis patients at 260 outpatient dialysis clinics,
showed that dialysis patients are at high risk of developing
COVID-19, and 90-day mortality ascribed to COVID-19
approaches 25% [7]. Among dialysis patients, residence in a
long-term care facility, Black race, male sex, diabetes, receipt of
in-centre dialysis and treatment at an urban dialysis centre
were identified as risk factors for COVID-19 infection. In dialysis
patients with COVID-19 disease, older age, hypertension,
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FIGURE 1: COVID-19 deaths per 100 000 population. Extracted from John Hopkins Coronavirus Resource Center (date: 25 January 2021).
FIGURE 2: Targeting of ACE2 by SARS-CoV-2 may result in Ang dysregulation, innate and adaptive immune pathway activation and hypercoagulation to result in organ
injury and AKI associated with COVID-19. Organ crosstalk between the injured lungs, the heart and the kidney may further propagate injury. CD8þ T cells and natural
killer cells can restrain macrophage activation and are potential targets for SARS-CoV-2. ATN, acute tubular necrosis; TMPRSS2, transmembrane protease, serine 2.
From Batlle et al. J Am Soc Nephrol 2020; 31: 1380–1383 [16] (with permission).
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congestive heart failure and peripheral vascular disease as well
as wheelchair use, were associated with higher risk of death [7].
The nephrology community throughout the world has
responded well to the challenges posed by COVID-19 and the
high demand for kidney replacement therapies for patients
with AKI and those already on dialysis.
In this issue, Dr Cozollino et al. describe strategies employed
to avoid COVID-19 infection in patients with end-stage kidney
disease and the important role of promoting home dialysis and
peritoneal dialysis [8]. In situations of medical crisis, epidemio-
logical studies for assessing mortality and outcomes in our dial-
ysis and transplant programmes are of the upmost importance,
as described by Dr Noordzij et al. Nephrologists have been
mainly trained to take care of patients, and yet the interpreta-
tion of emerging new studies is of crucial importance for the
progress of our specialty. Dr Noordzij et al. offer clues for inter-
preting epidemiological papers in the context of COVID-19 and
kidney disease. The authors bring up the need for awareness of
the differences in the study design, outcome definitions and ap-
plied methods that should help future and young investigators
to better interpret and design epidemiological studies in the ne-
phrology field [9]. Dr Toapanta et al. discuss COVID-19 in kidney
transplants, a topic of great importance since mortality in kid-
ney transplant recipients with COVID-19 infection has been es-
timated to be as high as 20%. Of note, incidence of AKI and the
need of renal replacement therapy in hospitalized kidney trans-
plant patients with COVID-19 infection is high. Whereas in the
general population, the variability of the reported AKI-related
COVID-19 infection is high and varies depending on the country
and type of study, studies performed in kidney transplant
patients showed consistent results with an incidence of AKI
around 45%. The occurrence of AKI risk in this specific CKD pop-
ulation is discussed by Toapanta et al. [10].
The impact of COVID-19 disease affects not only patients
with pre-existing kidney disease or kidney transplantation.
De novo kidney disease is commonly seen in hospitalized
patients with COVID-19, particularly those with severe disease
that require intensive care [11, 12]. In such patients, the inci-
dence of AKI is very high and is associated with high mortality
[13–15]. The pathophysiology of this form of AKI is not well un-
derstood, but several factors including activation of the innate
immune system, complement activation, Angiotensin (Ang) II
overactivity and the development of a hypercoagulable state
have been incriminated (Figure 2) [16]. In many patients, how-
ever, AKI is simply attributable to hypotension and sepsis.
Another entity that has been frequently described in patients
with COVID-19 is collapsing glomerulopathy, usually associated
with AKI and in African Americans with APOL risk alleles [17–
19].
Despite the intensity of medical care required to take care of
these sick patients with COVID-19 by the nephrology commu-
nity, there has also been an effort to convey the new informa-
tion that has been rapidly accrued during the past year. In this
issue of CKJ, Sharma et al. discuss AKI in COVID-19 patients,
reviewing the histopathological changes based on kidney biop-
sies and autopsies [20]. Drs Mohamed and Velez discuss the im-
portance of proteinuria including the assessment and methods
for its detection, the mechanisms involved and the significance
of ‘de novo’ proteinuria in COVID-19 patients [21].
Ang-converting enzyme 2 (ACE2) is the main receptor for
SARS-CoV-2 viral cell entry [22, 23]. In the kidney, ACE2 is pre-
sent mainly in the apical border of the proximal tubular cells
and, to a lesser extent, in podocytes (Figure 3) [24]. It is still a
matter of some debate whether kidney SARS-CoV-2 invasion
causes, in part, the manifestations of COVID-19 described
above. There are a few studies that have documented well the
presence of SARS-CoV-2 in the glomerulus and in proximal
tubular cells [25].
Following the recognition in January 2020 that ACE2 is the
receptor for SARS-CoV-2, like SARS-CoV, concerns were raised
that some drugs such as the renin–Ang system (RAS) blockers
could be deleterious in COVID-19 patients [26]. The concern was
based on studies prior to COVID-19, most of them in experimen-
tal animals, showing that ACE2 could be upregulated in the
FIGURE 3: A depiction of ACE2, the main receptor of SARS-CoV-2, in glomerular podocytes using immunogold labelling (left) and proximal tubular cells by immunofluo-
rescence (right). GBM, glomerular basement membrane. Data modified from Ye et al. J Am Soc Nephrol 2006; 17: 3067–3075 [24].
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heart, kidney vasculature and other organs [27, 28]. Recent work
has shown, however, that in the lungs, the site of SARS-CoV-2
entry, ACE2 expression is not increased [29]. After the initial
concern, several publications and position statements by scien-
tific specialty societies reassured the medical community that
there were no grounds to abandon these medications pending
studies addressing this issue [30–32]. In this issue, Cohen et al.
provide a critical review of the physiologic and epidemiologic
evidence of the interactions between RAS blockade and COVID-
19 that, in our opinion, brings this ongoing discussion towards
an end [33]. One year later, after all the concerns were raised
and with multiple publications addressing this issue, it seems
quite clear that the use of RAS blockers is generally safe in the
context of COVID-19.
In summary, this issue of CKJ covers current knowledge of
COVID-19 disease and its impact on the kidney. It is hoped
that the various contributions will provide the nephrology
community with valuable information that is useful for the care
of patients with underlying kidney disease and those with the
pathologies that have emerged related to the COVID-19
pandemic.
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